Table 7.

Objective response rate of lenvatinib and TACE in proof-of-concept study

	Lenvatinib (n = 30)	TACE (n = 60)	p value Odds ratio (95% CI)
ORR	22 (73.3%)	20 (33.3%)	<0.001
			5.39 (1.90–6.67)
CBR (CR + PR + SD ≥24 weeks)	29 (96.7%)	22 (36.7%)	<0.001
			48.1 (7.01–2,073.85)
DCR	30 (100.0%)	33 (55.0%)
CR	2	4
PR	20	16
SD	8	12
Durable SD (SD ≥24 weeks)	7	2
PD	0	26
NE	0	2

ORR, objective response rate; CBR, clinical benefit rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable. Cited from Kudo et al. [34].